The Journal of Allergy and Clinical Immunology: In Practice
SupplementChanging Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies
Key words
Abbreviations used
Cited by (0)
The authors were part of an expert panel hosted by the Cohen Family Asthma Institute at National Jewish Health in Denver, Colorado. This activity is supported by an independent educational grant from Teva Pharmaceuticals.
Conflicts of interest: R. K. Katial has received consultancy fees and travel support from Teva Pharmaceuticals; has received consultancy fees from AstraZeneca and Meda; and has received lecture fees from Meda. G. W. Bensch has received consultancy and lecture fees and travel support from Teva Pharmaceuticals; and payment for lectures including service on speakers bureaus from AstraZeneca. W. W. Busse has received consultancy fees and travel support from Teva Pharmaceuticals; is on the Boston Scientific and Circassia Data Safety Monitoring Boards; is on the ICON Clinical Research Limited Study Oversight Committee; has received consultancy fees from Novartis, GlaxoSmithKline, Genentech, Roche, Pfizer, Merck, Boehringer Ingelheim, Sanofi, AstraZeneca, Takeda, Aerocrine, 3M, and PrEPBiopharm; has received research support from National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) and NIH-National Heart, Lung, and Blood Institute; and receives royalties from Elsevier. B. E. Chipps has received consultancy fees and travel support from Teva Pharmaceuticals; has received consultancy and lecture fees from AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, and Novartis. J. L. Denson declares no relevant conflicts of interest. A. N. Gerber has received consultancy fees from Teva Pharmaceuticals and Revon Systems, the latter outside the current work. J. S. Jacobs has received travel support from Teva Pharmaceuticals; has received consultancy fees from Teva Pharmaceuticals and Sanofi-Aventis; has received lecture fees from Teva Pharmaceuticals; and has received research support from Teva Pharmaceuticals, Genentech, and AstraZeneca. M. Kraft has received consultancy fees from Teva Pharmaceuticals and AstraZeneca; has received research support from the NIH, Chiesi, Roche, and Sanofi; and receives royalties from Elsevier. R. J. Martin has received consultancy fees from Teva Pharmaceuticals and PMD Healthcare; has received research support from MedImmune, NHLBI, and Chiesi Farmaceutici SpA; has received travel support from the Respiratory Effectiveness Group; and is on the advisory boards for AstraZeneca and Genentech. P. Nair has received travel support from Teva Pharmaceuticals; is on the scientific advisory boards for Teva Pharmaceuticals, AstraZeneca, and Sanofi; has received consultancy fees from Teva Pharmaceuticals, Sanofi, Roche, Daiichi Sankyo, Novartis, and Knopp; has received research support from AstraZeneca, Novartis, Sanofi, Boehringer Ingelheim, Roche, Teva Pharmaceuticals, and GlaxoSmithKline; and has received lecture fees from AstraZeneca, Novartis, and Teva Pharmaceuticals. M. E. Wechsler has received consultancy fees from Sepracor/Sunovion, Asthmatx/Boston Scientific, Merck, Regeneron, MedImmune, Ambitbio, Vectura, Sanofi, Teva Pharmaceuticals, Mylan, AstraZeneca, Genentech, Meda, Theravance, Novartis, Boehringer Ingelheim, GlaxoSmithKline, Tunitas, and Gliacure; and is on the advisory board for Teva Pharmaceuticals.